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Evidence before this study
Up to now, most reports of COVID-19 in individuals with Down
syndrome (DS) have been based on less than 10 individuals.
One recent report used primary care data from the UK which
includes 8 million adults with and without Down syndrome.
However, while only 37 of the 4053 individuals with Down
syndrome had COVID-19 (positive test result reported), 27
COVID-19 related deaths were reported among the individuals
with Down syndrome. As many individuals with Down syn-
drome might not have had access to their primary care physi-
cians during the first peak of the pandemic, this study may be
unrepresentative of mild cases.
Added value of this study
Our results, which are based on >1,000 COVID-19 patients with
DS, show that individuals with DS may present with more
severe symptoms at hospitalisation (e.g. confusion), and experi-
ence high rates of lung complications associated with increased
mortality. In terms of sheltering/shielding individuals to pre-
vent infection, more caution should be taken with individuals
over age 40, which is about 20 years younger than the typical
at-risk group in the general population. Individuals with DS
aged 40 and older have a three-fold increased risk for mortality
compared to the general population, which is not explained by
additional comorbidities.
Implications of all the available evidence
Individuals with DS (especially those older than 40 years) are
vulnerable to medical complications and increased risk for
death related to COVID-19. Therefore individuals with DS
should be considered a priority group for COVID-19
vaccination.1. Introduction
Down syndrome (DS), the result of the trisomy of chromosome 21,
is the commonest genetic cause for intellectual disability. It is associ-
ated with specific co-occurring health conditions and immune
dysfunction that may impact the clinical course and risk forcal vulnerability of individua
vey, EClinicalMedicine (2021life-threatening disease due to infection by the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) [1].
Immune-response dysfunction associated with trisomy 21
includes alterations in the number of different types of immune cells
(T- and B-cells, monocytes and neutrophils) [2] and adverse antibody
responses [3]. The unusual inflammatory profile of individuals with
DS is associated with more severe illness following viral infections,
such as the viral infection during the H1N1 influenza pandemic [4],
respiratory syncytial virus (RSV) [5], and may also lead to worse out-
comes due to coronavirus disease 2019 (COVID-19). The cytokine
storm reported to be associated with COVID-19 [6], refers to an
excessive immune response to external stimuli and is thought to be a
predictor of increased severity of SARS-CoV-2 infection and of poor
COVID-19 prognosis [7]. Admission to intensive care units (ICU) fol-
lowing COVID-19 diagnoses was found to be associated with higher
plasma levels of many cytokines [7]. Individuals with DS frequently
display elevated levels of cytokines in blood, even in the absence of
viral infection, and a proinflammatory profile that includes increased
numbers of natural killer (NK) cells and CD8+ T-cells, decreased CD19
+ B-cell counts, and an increased spontaneous production of inter-
feron gamma, TNFa, and IL-10 [8,9]. Recent findings in this fast-
evolving field, however, suggest COVID-19 may not be characterized
by a cytokine storm after all [10]. Moreover, it is also reasonable to
speculate that increased levels of cytokines, particularly interferon
gamma, may actually help patients fight off the SARS-CoV-2 infec-
tion.
DS is associated with several co-occurring health conditions
including obesity, diabetes, hypotonia, obstructive sleep apnea, cra-
niofacial dysmorphogenesis, and congenital heart defects, as well as
gastroesophageal reflux that may contribute to the increased risk of
respiratory tract infection [1,1113]. Moreover, adults with DS have
many age-related health conditions including Alzheimer’s disease
[14], that often occur 2025 years earlier than in individuals without
DS which is a profile that suggests premature aging [1,11,14]. Yet,
there is also evidence that persons with DS are protected from car-
diovascular disease, including hypertension [15]. Additionally, the
incidence and severity of various comorbid conditions are quite vari-
able among people with DS. Therefore, it is difficult to predict
whether individuals with DS are particularly susceptible to COVID-19
and its complications.
In the US and many European countries, individuals with DS older
than 40 years of age tend to live in group homes and other assisted-
living situations [16]. Furthermore, it is not uncommon for those
with DS in their 50 and 60’s to dwell in nursing homes for prolonged
periods. These living spaces, which many times are occupied by sev-
eral individuals and frequently visited by multiple support staff, havels with Down syndrome to severe COVID-19data from the Trisomy
), https://doi.org/10.1016/j.eclinm.2021.100769
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older individuals in the general population [17]. Therefore, one issue
of particular importance is ascertaining whether individuals with DS
are at increased risk for hospitalization and mortality following
COVID-19 diagnosis at a younger age than their counterparts without
DS. However, up to now, most reports of COVID-19 in individuals
with DS have been based on less than 10 individuals [18,19]. One
recent report used primary care data from the UK, but included a
small sample of individuals with DS who have died (n = 27), and may
be unrepresentative of mild cases, due to patients not having access
to their primary care physicians during the first peak of the pandemic
[20].
In order to obtain large scale information on specific vulnerabil-
ities, clinical presentation, and outcomes of COVID-19 in individuals
with DS, the Trisomy 21 Research Society (T21RS) launched an online
survey, with input from stakeholders including leading clinicians and
DS organisations (details provided in the acknowledgements). The
survey was designed to address three primary questions: 1) What are
the presenting signs and symptoms of COVID-19 in individuals with
DS and are these different than in individuals without DS? 2) Are
those with DS at an increased risk for complications associated with
SARS-CoV-2 infection? 3) Is the profile of risk factors associated with
poor outcomes for COVID-19 in persons with DS the same as in the
general population? Here we report on the data collected from
Europe, United States (US), Latin America, India, as well as hospital
data from other sources.
2. Methods
2.1. T21RS DS survey
An online survey was developed in March 2020, to identify
patients with COVID-19 among individuals with DS (a copy of the
survey is provided in the supplementary material). Two equivalent
surveys were developed, one to be completed by caregivers/family
members of COVID-19 affected individuals with DS and one to be
completed by clinicians. Most often, either the caregiver or the clini-
cian completed the survey per person. When both forms were com-
pleted for the same individual (i.e., linked surveys), information was
combined to maximize the amount of available data per person. The
survey collected information on: 1) basic demographics, 2) living sit-
uation during the pandemic, 3) pre-existing health conditions, vacci-
nations and medications, 4) SARS-CoV-2 testing, 5) presenting signs
and symptoms, 6) hospital and ICU admission, 7) complications asso-
ciated with SARS-CoV-2 infection (clinician only), 8) medications and
treatments used during COVID-19 illness (clinician only), and 9) sta-
tus at last evaluation. The survey was implemented through REDCap
[21,22], a survey and database management system, and was hosted
at Emory University. As we include data from the early phase of the
COVID-19 pandemic and the testing capacities differ between coun-
tries, we use the term “case” to refer to individuals with DS of all
ages, who tested positive for SARS-CoV-2 or reported signs or symp-
toms of COVID-19. The survey was disseminated through clinical
routes (e.g. Down syndrome medical interest group listservs and
health service providers), Down syndrome associations in the US,
India, Spain, UK, France, Italy, Germany, Brazil, and Spanish-speaking
Latin America, and DS registries (e.g., NIH DS-Connect) as well as via
the T21RS website.
2.2. Ethics statement
Each institution that planned to disseminate the survey within
health services obtained IRB/ethics approval (Table S1). The study
was performed according to the Declaration of Helsinki and national
guidelines and regulations for data privacy and all participants who
completed the questionnaires provided informed consent. All dataPlease cite this article as: A. H€uls et al., Medical vulnerability of individua
21 Research Society and the UK ISARIC4C survey, EClinicalMedicine (2021were anonymized according to good clinical practice guidelines and
data protection regulations.
2.3. Statistical analysis
For this analysis, we included data from all cases that were
entered between April 9, 2020 and October 22, 2020. Only individuals
with information on age and gender were included in the analyses.
We used descriptive statistics to show the demographic information,
COVID-19 signs, symptoms, outcomes, and comorbidities of the par-
ticipants included in our analyses. To prevent study participants from
being included twice in the analyses (reported by both caregiver and
clinician), we excluded duplicated participants based on age, gender
and country and other specific demographics.
To contrast the COVID-19 related signs, symptoms, and medical
complications with those observed in the general population, we
compared the T21RS DS cases to data from the UK ISARIC4C survey.
The ISARIC4C survey is a prospective observational cohort study
engaging 208 acute-care hospitals in England, Wales, and Scotland
[23]. In this study, we included 59,025 hospitalized patients with
COVID-19 from the ISARIC4C survey, which were entered between
February 2020 and July 9, 2020 (downloaded on July 24, 2020).
Among the 59,025 hospitalized patients, 109 individuals had DS
(58,916 did not). Of these, 100 had complete data on age, gender and
ethnicity. These 100 individuals, referred to as “ISARIC4C DS cases”,
were matched to 400 COVID-19 patients without DS (referred to as
“controls”) from the same survey (matching 1:4). To account for dif-
ferences in study design and country-specific differences between
the UK ISARIC4C survey and the international T21RS survey, we used
the hospitalized patients with DS from the ISARIC4C survey as start-
ing point and matched those to hospitalized patients in the T21RS
dataset based on age, gender and ethnicity. Only a 1:1 match was
possible because of matching criteria (see supplementary tables S2
and S3 for characteristics of the matched samples). While this match-
ing procedure reduced our sample size from 586 to 100 T21RS cases,
it added an additional level of confidence because we were able to
conduct two comparisons - ISARIC4C patients without DS (i.e., con-
trols) versus ISARIC4C patients with DS (i.e., ISARIC4C DS cases) and
ISARIC4C controls versus T21RS patients with DS. Fisher’s exact test
was used to probe for differences in the prevalence of signs, symp-
toms, and medical complications between matched hospitalized
cases with DS (from the ISARIC4C and T21RS surveys) and without
DS (controls from the ISARIC4C survey).
To compare the mortality rates of hospitalized COVID-19 patients
with and without DS in different age groups, we combined data from
different sources. Case counts and mortality rates among hospitalized
patients from the general population were estimated from individu-
als without DS included in the UK ISARIC4C survey combined with
published hospital reports from Spain [24] and New York City [25].
Mortality rates among hospitalized patients with DS were based on
combined data from the UK ISARIC4C survey and hospitalized indi-
viduals from the T21RS survey. In addition, we used the matched
samples described above to perform a comparison of mortality rates
corrected for age, gender and ethnicity using logistic regression. To
test whether differences in mortality rates of individuals with and
without DS can be explained by differences in the prevalence of
known risk factors for COVID-19-related mortality, we adjusted the
association analyses for chronic cardiac disease, chronic pulmonary
disease, chronic kidney disease, liver disease, obesity, chronic neuro-
logical disorder, dementia, malignant neoplasm [23]. In a sensitivity
analysis, we analysed the association between DS and COVID-19-
related mortality in the whole ISARIC4C sample (52,142 individuals
without DS and no missing data for age, gender and ethnicity, 100
individuals with DS) adjusted for i) age, gender and ethnicity and ii)
additionally for chronic cardiac disease, chronic pulmonary disease,
chronic kidney disease, liver disease, obesity, chronic neurologicalls with Down syndrome to severe COVID-19data from the Trisomy
), https://doi.org/10.1016/j.eclinm.2021.100769
Table 1
T21RS study characteristics grouped by data source (reported by clinician versus
family/caregiver).
Overall Clinician survey Family survey




52 (5.0) 27 (4.6) 25 (5.5)
Country (%)
India 405 (39.7) 218 (37.8) 187 (42.3)
United States 163 (16.0) 90 (15.6) 73 (16.5)
Spain 155 (15.2) 113 (19.6) 42 (9.5)
Brazil 75 (7.4) 32 (5.5) 43 (9.7)
United Kingdom 72 (7.1) 27 (4.7) 45 (10.2)
France 67 (6.6) 61 (10.6) 6 (1.4)
Italy 35 (3.4) 20 (3.5) 15 (3.4)
other2 47 (4.6) 16 (2.8) 31 (7.0)
Age in years (mean (SD)) 29.35 (17.92) 35.58 (18.12) 21.26 (14.01)
Male (%) 564 (54.0) 336 (56.9) 228 (50.3)
Ethnicity (%)
White 440 (42.1) 247 (41.8) 193 (42.4)
South Asian 414 (39.6) 225 (38.1) 189 (41.5)
Latin American 49 (4.7) 19 (3.2) 30 (6.6)
Black 17 (1.6) 13 (2.2) 4 (0.9)
Arab 2 (0.2) 1 (0.2) 1 (0.2)
East Asian 1 (0.1) 1 (0.2) 0 (0.0)
West Asian 1 (0.1) 1 (0.2) 0 (0.0)
Admixed3 23 (2.2) 13 (2.2) 10 (2.2)
Unknown 99 (9.5) 71 (12.0) 28 (6.2)
Living situation (%)
Living at home with
family
712 (73.3) 307 (59.0) 405 (89.6)
Living alone with support 7 (0.7) 4 (0.8) 3 (0.7)
Small group home with
support
89 (9.2) 71 (13.7) 18 (4.0)
Residential care facility 157 (16.2) 134 (25.8) 23 (5.1)
Other 7 (0.7) 4 (0.8) 3 (0.7)
Type of trisomy 21 (%)
Full/standard 784 (92.5) 401 (93.0) 383 (91.8)
Mosaic 51 (6.0) 24 (5.6) 27 (6.5)
Partial trisomy 4 (0.5) 2 (0.5) 2 (0.5)
Translocation 9 (1.1) 4 (0.9) 5 (1.2)
Level of intellectual disabil-
ity (%)
Borderline/normal/mild 169 (18.1) 77 (14.8) 92 (22.3)
Moderate 580 (62.2) 314 (60.3) 266 (64.6)
Severe/Profound 184 (19.7) 130 (25.0) 54 (13.1)
Admitted to hospital (%) 581 (56.0) 388 (65.9) 193 (43.1)
Days in hospital (mean
(SD))4
12.90 (9.29) 13.05 (8.50) 12.62 (10.68)
Admitted to ICU (%)4 279 (49.6) 185 (49.7) 94 (49.5)
Days in ICU (mean (SD)) 4 8.46 (4.91) 8.57 (4.85) 8.25 (5.04)
Mechanical ventilation
(%)4
207 (28.5) 131 (24.9) 76 (37.8)
Clinical situation at last eval-
uation (%)
Currently in hospital with
symptoms
136 (13.7) 85 (14.9) 51 (12.0)
Died 131 (13.2) 114 (20.0) 17 (4.0)
Not currently in hospital
but with symptoms
130 (13.1) 46 (8.1) 84 (19.8)
Other 27 (2.7) 5 (0.9) 22 (5.2)
Recovered from COVID-19 547 (55.0) 303 (53.1) 244 (57.5)
Tested positive but still no
symptoms
24 (2.4) 18 (3.2) 6 (1.4)
1 When both the clinician and caregiver/family member surveys were completed
for a participant with DS (linked survey), information from each source were com-
bined (clinician linked to the family survey and family linked to the clinician survey,
see methods for more details
2 countries with fewer than 10 individuals were summarized as “other”. These
include Argentina (4 cases), Germany (4 cases), Mexico (4 cases) and other countries
with <4 cases reported. 3The category “admixed” refers to individuals who selected
more than one ethnic groups. 4Only answered if admitted to hospital; % were calcu-
lated after excluding missing information
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age-stratified association analyses for individuals younger than
40 years versus 40 years or older.
To identify risk factors associated with adverse outcomes of
COVID-19 in individuals with DS, we conducted adjusted logistic
regression analyses in symptomatic COVID-19 cases from the T21RS
survey data. Associations between potential risk factors and admis-
sion to hospital or all-cause mortality were analysed. Associations
with age and gender were adjusted for the data source (caregiver ver-
sus clinician survey) and associations with living situation, level of
intellectual disability, and comorbidities were adjusted for age, gen-
der, data source and country of residence. We only included comor-
bidities that were present in at least 15% of our study samples to
reduce the burden of multiple testing and the chance of false posi-
tives due to small numbers of cases.
We did all data analyses using R (version 4.0.0).
2.4. Role of the funding sources
Funding sources provided help with dissemination of the online
surveys and partial support of the biostatisician’s efforts. They were
not involved in: the study design; collection, analysis, or interpreta-
tion of data; writing of the manuscript; or in the decision to submit
the paper for publication.
3. Results
3.1. Description of study population
Of the 1906 records in the T21RS database entered between April
9, 2020 and October 22, 2020, 1103 individuals had signs and symp-
toms of COVID-19 or a positive test result and provided information
on age and gender. After removing potential duplicates, the final
sample size was 1046 COVID-19 patients with DS (Figure S1). The
majority of these cases were symptomatic (981 (94.5%)) and 861
(83%) were tested for COVID-19 (750 (91%) with a positive test result)
(Table S4). Of the 1046 COVID-19 patients with DS, 591 (57%) were
reported by a clinician and 455 (43%) by a family member or care-
giver (Table 1). The largest number of cases were from India (405
(40%)), followed by the United States (163 (16%)), Spain (155 (15%))
and Brazil (75 (7%)). The mean age was 29 years (SD=18); cases
reported by a clinician were on average 15 years older than cases
reported by a family member or caregiver. The majority of cases lived
at home with their family (712 (73%)). The proportion of cases living
in a residential care facility was higher in the clinician than family/
caregiver reports (134 (26%) versus 23 (5%)). The majority of cases
(784 (93%)) had full trisomy 21 and moderate level of intellectual dis-
ability (580 (62%)), similar to that observed in the population of indi-
viduals with DS at large [11]. About half of the cases were admitted
to hospital (581 (56%)), of which 279 (50%) were admitted to an ICU
and 207 (29%) were connected to a mechanical ventilator. More than
half of the cases (547 (55%)) had recovered from COVID-19 at the last
evaluation.
3.2. Signs and symptoms presenting in COVID-19 patients with DS and
without DS
The leading signs and symptoms related to COVID-19 in individu-
als with DS were fever, cough and shortness of breath (Fig. 1, Table 2),
which is in line with those reported in the general population
(Table 2, ISARIC4C controls). Nasal signs (excess nasal drainage or
‘runny nose’) and pharyngitis (‘sore throat’) were also common
among COVID-19 patients from the T21RS survey, particularly in chil-
dren and adolescents (younger than 20 years), where nasal signs
were present in 229 (61%) and sore throat in 165 children and adoles-
cents (44%) independent of the data source (family or clinicianPlease cite this article as: A. H€uls et al., Medical vulnerability of individuals with Down syndrome to severe COVID-19data from the Trisomy
21 Research Society and the UK ISARIC4C survey, EClinicalMedicine (2021), https://doi.org/10.1016/j.eclinm.2021.100769
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iting (26%) and muscle or joint pain (18%) were particularly common
in the age group 2030 years. Signs and symptoms that were more
prevalent in individuals with DS 40 years and older include extreme
fatigue or confusion (30%) and not eating or drinking (21%).
Family members and caregivers tended to report more signs and
symptoms, and more often reported extreme fatigue and confusion
than clinicians, particularly in individuals 40 years and older (clini-
cian reports: 73/284 (26%), family reports: 25/51 (49%); Figure S2).
The signs and symptoms reported for cases with a positive test result
did not differ from those reported for the whole study sample (e.g.
fever, cough and shortness of breath were reported in 77%, 50% and
48%, respectively, of all cases and 80%, 47% and 54% of the cases with
a positive test result; Figure S3). Furthermore, reported signs and
symptoms were similar between individuals with mild-to-moderate
and severe intellectual disability (e.g. fever, cough and shortness of
breath were reported in 79%, 51% and 48%, respectively, of cases with
mild-to-moderate and 79%, 52% and 52% of the cases with severe
intellectual disability; Figure S4). Individuals admitted to hospital
had more signs and symptoms in general compared with those who
were not hospitalized, with shortness of breath being particularly
more common among individuals admitted to hospital (66% versus
26%, Fig. S5).
Comparing the signs and symptoms of hospitalized individuals
with DS to matched individuals without DS (based on age, gender,Fig. 1. Signs and symptoms reported among the COVID-19 cases with Down syndrome grou
tivitis” and “skin lesions”were added in the second wave of the survey (smaller sample size f
Please cite this article as: A. H€uls et al., Medical vulnerability of individua
21 Research Society and the UK ISARIC4C survey, EClinicalMedicine (2021and ethnicity) showed that joint pain or muscle aches was less fre-
quently reported in individuals with DS (controls: 29%, ISARIC4C DS:
5%, (p < 0.001), T21RS DS: 11% (p < 0.001), Table 2). Altered con-
sciousness or confusion was more frequently reported in individuals
with DS (controls: 18%, ISARIC4C DS: 33% (p = 0.004), T21RS DS: 32%
(p = 0.003)) and vomiting/nausea was less often reported in individu-
als with DS (controls: 27%, ISARIC4C DS: 11% (p = 0.003), T21RS DS:
14% (p = 0.008)). Nasal signs were more often reported in individuals
with DS only from the T21RS survey, which might be due to differen-
ces in study design (ISARIC4C: hospital reports by clinicians; T21RS:
voluntary online survey by family or clinicians).
3.3. Medical complications among COVID-19 patients with and without
DS
Overall, 360 (60%) of the T21RS DS cases reported by clinicians
had developed medical complications due to COVID-19 (medical
complications were not included in the caregiver survey, Table S5).
Experiencing medical complications was correlated with higher mor-
tality rates. The most prevalent complications were viral pneumonia
(36%) and acute respiratory distress syndrome (34%), followed by sec-
ondary bacterial pneumonia (17%) and septic shock (11%). Of the
individuals who died, 69% had viral pneumonia and 85% an acute
respiratory distress syndrome. The prevalence of medical complica-
tions increased by age. While 64 (41%) of the 019 year-oldsped by age (T21RS survey). The signs and symptoms “not eating or drinking”, “conjunc-
or these symptoms).
ls with Down syndrome to severe COVID-19data from the Trisomy
), https://doi.org/10.1016/j.eclinm.2021.100769
Table 2
Signs and symptoms related to COVID-19 in individuals with and without Down syndrome. Hospitalized individuals with Down syndrome from the UK ISARIC4C
and the T21RS surveys are compared to matched hospitalized individuals without Down syndrome (controls) from the ISARIC4C survey. The 100 individuals
with Down syndrome reported through the UK ISARIC4C survey were matched to 400 individuals without Down syndrome (controls) from the same survey
(matching 1:4) as well as to 100 individuals with Down syndrome from the T21RS survey (matching 1:1). The matching was based on age, gender and ethnicity
(see supplementary tables S2 and S3 for characteristics of the matched samples).
ISARIC4C controls ISARIC4C individuals with Down syndrome T21RS matched individuals with Down syndrome
n (%) N n (%) N p value (comparison
with controls)
n (%) N p value (comparison
with controls)
Cough1 270 (71.8) 376 65 (67.7) 96 0.451 54 (54.0) 100 0.001
Fever 294 (76.4) 385 64 (68.1) 94 0.112 80 (80.0) 100 0.505
Sore throat 39 (13.0) 301 8 (12.1) 66 1.000 17 (17.0) 100 0.320
Runny nose2 13 (4.4) 293 2 (3.3) 61 1.000 16 (16.0) 100 <0.001
Joint pain or muscle aches 90 (28.8) 313 3 (4.8) 63 <0.001 11 (11.0) 100 <0.001
Fatigue/Malaise3 149 (46.4) 321 33 (45.8) 72 1.000 32 (32.0) 100 0.011
Shortness of breath 248 (68.9) 360 66 (74.2) 89 0.368 76 (76.0) 100 0.176
Disturbance or loss of taste/smell4 15 (9.3) 162 0 (0.0) 27 0.206 3 (3.0) 100 0.076
Headache 55 (18.3) 301 2 (3.1) 64 0.001 14 (14.0) 100 0.362
Altered consciousness or confusion3 61 (17.6) 346 25 (32.9) 76 0.004 32 (32.0) 100 0.003
Abdominal pain 60 (18.2) 330 10 (14.3) 70 0.493 11 (11.0) 100 0.094
Vomiting/nausea 92 (27.0) 341 8 (10.7) 75 0.003 14 (14.0) 100 0.008
Diarrhoea 77 (23.1) 334 10 (12.3) 81 0.034 17 (17.0) 100 0.216
Skin rash or skin ulcers5 13 (4.0) 321 4 (5.1) 78 0.754 2 (x) 44 0.700
1 ISARIC4C: combination of the signs “cough”, “cough with sputum production” and “cough bloody sputum / haemoptysis”;
2 The T21RS survey asked for the presence of “nasal signs”;
3 In the T21RS survey, this is referred to as “extreme fatigue, confusion, difficulty staying alert”;
4 ISARIC4C: combined ageusia and anosmia;
5 ISARIC4C: combined skin rash and skin ulcers; n/a: these questions were not included in the T21RS survey; % were calculated after excluding missing
information.
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increased to 103 (65%) in 2039 year-olds and 193 (69%) in individu-
als with DS 40 years or older (Table S6).
Comparing the medical complications observed in hospitalized
patients with DS to matched patients without DS (based on age, gen-
der and ethnicity) showed that pulmonary complications (pneumo-
nia and acute respiratory syndrome) were more common in
individuals with DS (Table 3). These differences were significant for
all three pulmonary complications (viral pneumonia, bacterial pneu-
monia and acute respiratory syndrome) comparing the T21RS data to
the ISARIC4C controls (p < 0.01) and suggestive for the comparison
of viral pneumonia within the ISARIC4C data (p = 0.059). There was
no difference in the frequency of cardiac complications, anaemia, or
acute renal injury. Among those with COVID-19-related viral pneu-
monia, individuals with DS were more likely to die than individuals
without DS (controls: 23%, ISARIC4C DS: 53% (p < 0.001); T21RS DS:
57% (p < 0.001)). Mortality rates were also higher among patients
with DS and acute respiratory syndrome and cardiac complications,
but the differences were only significant for the comparison between
the T21RS DS cases to the ISARIC4C controls (acute respiratory syn-
drome: controls: 36%, ISARIC4C DS: 47% (p = 0.563); T21RS DS: 75%
(p < 0.001); cardiac complications: controls: 31%, ISARIC4C DS: 33%
(p = 1.000); T21RS DS: 100% (p = 0.007)). Overall, medical complica-
tions were more common in the T21RS data than in individuals with
DS from the ISARIC4C survey and the frequencies differed between
countries, with India, Spain and United States reporting the highest
numbers of medical complications (Table S7). Thus, observed differ-
ences might be due to differences in study design or due to small
numbers (e.g., cardiac complications).
3.4. Mortality rates among COVID-19 patients with and without DS
Overall, 13% of the 1046 COVID-19 patients with DS from the
T21RS DS data died (Table 1). Eighty-seven percent of the fatal out-
comes were reported by clinicians; 13% were reported by family
members or caregivers. The mean age of cases who died was 51 years
(SD = 12), whereas the mean age of cases who did not die was
27 years (SD = 17) (Table S8).Please cite this article as: A. H€uls et al., Medical vulnerability of individua
21 Research Society and the UK ISARIC4C survey, EClinicalMedicine (2021Among individuals with DS who were hospitalized with COVID-
19, we observed an increased mortality rate from age 40, while in the
general population mortality rate increased at age 60 (Fig. 2A, Tables
S9 and S10). Mortality rates under the age of 40 were low, but still
higher in patients with DS than in the general population (7% of hos-
pitalized COVID-19 patients with DS died, compared to 3% in the gen-
eral population; Fig. 2A).
Comparing mortality rates among the matched ISARIC4C and
T21RS samples, individuals with DS hospitalized with COVID-19
were around three times more likely to die than individuals without
DS, assuming the same age, gender and ethnicity (Fig. 2B, individuals
with and without DS from ISARIC4C: risk ratio (RR) = 2.9 (95%-
CI = 2.1; 3.8), individuals with DS from T21RS vs. individuals without
DS from ISARIC4C: RR = 3.5 (95%-CI = 2.6; 4.4)). Adjusting for known
COVID-19 related risk factors for mortality (chronic cardiac disease,
chronic pulmonary disease, chronic kidney disease, liver disease, obe-
sity, chronic neurological disorder, dementia, malignant neoplasm),
reduced the RR to 2.5 (95%-CI = 1.5; 3.7) (ISARIC4C DS versus controls,
Table S11A). That means that even after accounting for known risk
factors, individuals with DS were still 2.5 times more likely to die
after being hospitalized with COVID-19. However, mortality rates of
individuals younger than 40 years of age were substantially lower
(3% in controls, 12% in matched individuals with DS from the ISAR-
IC4C survey and 13% in matched individuals from the T21RS survey),
which is in line with mortality rates in individuals under the age of
40 with and without DS from the whole study sample (Fig. 2A, Tables
S5 and S6). The differences in mortality rates between these younger
individuals with and without DS were not significant after adjusting
for known risk factors for COVID-19 mortality (chronic cardiac dis-
ease, chronic pulmonary disease, chronic kidney disease, liver dis-
ease, obesity, chronic neurological disorder) (RR = 2.4, 95%-CI = 0.1;
12.9, Table S11B), suggesting that excess mortality in younger indi-
viduals with DS was potentially due to differences in comorbid condi-
tions or to small sample sizes of those who died. However, comparing
individuals with DS younger than 40 and those over 40 admitted to
hospital while adjusting for comorbidities known to be associated
with COVID-19 and those common in DS, suggest that the reduction
in risk for mortality is between 68% (95%-CI 1893%; ISARIC4C
ls with Down syndrome to severe COVID-19data from the Trisomy
), https://doi.org/10.1016/j.eclinm.2021.100769
Table 3
Medical complications related to COVID-19. Prevalence of cardiac complications and other medical complications that occurred in at least 10% of the matched control group and the
associated mortality rate. Hospitalized individuals with Down syndrome from the UK ISARIC4C and the T21RS surveys are compared to matched individuals without Down syn-
drome (controls) from the ISARIC4C survey. The 100 individuals with Down syndrome reported through the UK ISARIC4C survey were matched to 400 individuals without Down
syndrome (controls) from the same survey (matching 1:4) as well as to 100 individuals with Down syndrome from the T21RS survey (matching 1:1). The matching was based on
age, gender and ethnicity (see supplementary tables S2 and S3 for characteristics of the matched samples).
A. Prevalence of medical complications among hospitalized patients
ISARIC4C controls ISARIC4C individuals with Down syndrome T21RS individuals with Down syndrome
n (%) N n (%) N p value (comparison
with controls)
n (%) N p value (comparison
with controls)
Viral pneumonia1 151 (42.7) 354 49 (53.8) 91 0.059 60 (83.3) 72 <0.001
Bacterial pneumonia 35 (10.0) 351 14 (15.2) 92 0.189 8 (32.0) 25 0.004
Acute Respiratory Syndrome 47 (13.0) 362 17 (17.9) 95 0.245 41 (60.3) 68 <0.001
Cardiac complications2 32 (8.6) 370 6 (6.3) 95 0.535 5 (8.5) 59 1.000
Anaemia 43 (11.7) 367 11 (12.0) 92 1.000 n/a n/a n/a
Acute renal injury/Acute renal failure 51 (13.8) 369 12 (12.8) 94 0.867 11 (17.7) 62 0.434
B. Associated mortality rate
Viral pneumonia1 34 (22.5) 151 26 (53.1) 49 <0.001 34 (56.7) 60 <0.001
Bacterial pneumonia 11 (31.4) 35 6 (42.9) 14 0.516 2 (25.0) 8 1.000
Acute Respiratory Syndrome 17 (36.2) 47 8 (47.1) 17 0.563 31 (75.6) 41 <0.001
Cardiac complications2 10 (31.3) 32 2 (33.3) 6 1.000 5 (100.0) 5 0.007
Anaemia 14 (32.6) 43 4 (36.4) 11 1.000 n/a n/a n/a
Acute renal injury/Acute renal failure 19 (37.3) 51 5 (41.7) 12 1.000 7 (63.6) 11 0.177
1 T21RS survey: In the 1st wave of our survey, we only asked for pneumonia without differentiating between viral and bacterial pneumonia. As most clinicians answered this
question with information on COVID-19-related viral pneumonia, the information provided on “pneumonia” in the 1st wave of the survey was combined with “viral pneumonia” for
the analyses. Combination of cryptogenic organizing pneumonia (COP), pneumothorax, pleural effusion, bronchiolitis;
2 ISARIC4C: Combination of congestive heart failure, endocarditis / myocarditis pericarditis, myocarditis / pericarditis, cardiomyopathy, cardiac arrhythmia, cardiac ischemia; %
were calculated after excluding missing information.
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ger individuals compared with those over 40 (table S12).
3.5. Risk Factors for hospitalization and mortality among COVID-19
patients with DS
Age was the strongest risk factor for hospitalization and mortality
in individuals with DS from the T21RS survey (Fig. 3, Table S13).
Every additional 10 years of age increased the odds for hospitaliza-
tion by a factor of 1.75 (95%-CI = 1.47; 2.07) and the odds for mortal-
ity by a factor of 2.41 (95%-CI = 2.02; 2.89). We further observed
increased odds for hospitalization for males (OR (95%-CI) = 1.51
(1.16; 1.97)), individuals with obesity (OR (95%-CI) = 2.03 (1.44;
2.87)), diabetes (OR (95%-CI) = 1.93 (1.2; 3.1)) and individuals with a
congenital heart defect (OR (95%-CI) = 1.46 (1.05; 2.03)). We observed
increased odds for mortality for males (1.75, 95% CI = 1.16-2.63) and
individuals with Alzheimer’s disease/dementia (OR (95%-CI) = 2.13
(1.1; 4.12)). Other potential risk factors (living in residential care
facility, level of intellectual disability, thyroid disorder, seizures/epi-
lepsy, obstructive sleep apnea, gastroesophageal reflux, behavioral
and psychiatric condition and chronic lung disease) were not signifi-
cant (Fig. 3, Table S13).
4. Discussion
DS is associated with specific co-occurring conditions and an
immune-response dysfunction that may impact the risk of individu-
als with this disorder for having a more severe course of illness fol-
lowing infection by SARS-CoV-2. To examine this question, we
conducted an international online survey to collect COVID-19 related
information on signs and symptoms, course of disease, and potential
risk factors in more than 1,000 patients with COVID-19 and DS, by far
the largest assessment of individuals with DS who were infected
with SARS-CoV-2 that has been reported to date. Our analyses
showed that while the leading signs and symptoms related to
COVID-19 are similar to those in the general population, patients
with DS who are hospitalized with COVID-19 were more likely to
experience a severe course of disease with higher rates of medicalPlease cite this article as: A. H€uls et al., Medical vulnerability of individua
21 Research Society and the UK ISARIC4C survey, EClinicalMedicine (2021complications and mortality than the general population, particularly
adults older than 40 years of age.
Similar to the general population, fever, cough and shortness of
breath were the leading signs and symptoms related to COVID-19 in
individuals with DS [23]. From the general population, we know that
COVID-19 is usually a mild disease in children and often accompanied
with a few upper respiratory symptoms, including nasal congestion
and runny nose [26]. Interestingly, we found that nasal signs were
much more common in individuals from our T21RS survey than in
individuals with and without DS from the ISARIC4C survey (hospital
reports from the UK), which may relate to earlier signs of COVID-19
occurring prior to hospitalization or to different reporting by fami-
lies/caregivers. This highlights the importance of including data from
community-dwelling individuals with COVID-19 in addition to rou-
tine hospital reports as hospital reports are less likely to capture mild
signs and symptoms that might be important for early detection of
disease. Loss of smell or taste was reported in less than 10% of indi-
viduals with DS, which was similar to the numbers reported in indi-
viduals without DS from the ISARIC4C survey, but much lower than
the prevalence reported by other studies (48% loss of smell and 41%
loss of taste as summarized in reference [27]). The most likely expla-
nation for these differences to more recent studies is that most T21RS
and ISARIC4C cases were reported during the first wave of the pan-
demic, when we had very little knowledge about the variety of
COVID-19 symptoms leading to an underdiagnosis of smell and taste
disorders. Future studies are needed to determine if intellectual dis-
abilities are also linked with an underdiagnosis of these symptoms.
Altered consciousness or confusion were more commonly
observed in individuals with DS than in the general population. As
this sign could be an indicator of disease severity, it suggests that
individuals with DS are more likely to become severely ill with
COVID-19 than individuals without DS, or that they might be more
severely ill at the time of hospitalization. Joint pain or muscle aches
and vomiting/nausea were less commonly reported in individuals
with vs. without DS. There is little evidence that people with DS
experience both acute and chronic pain with a lower frequency than
the rest of the population [28]. However, there is some evidence that
parental perception of pain is less discriminant for children with DSls with Down syndrome to severe COVID-19data from the Trisomy
), https://doi.org/10.1016/j.eclinm.2021.100769
Fig. 2. Mortality rates among patients hospitalized with COVID-19. A. Age distribution of the proportion of deaths among individuals with DS (combined data from the T21RS and
ISARIC4C surveys), who were hospitalized with COVID-19, in comparison to hospitalized cases of COVID-19 from the general population (combined data from the UK ISARIC4C sur-
vey (patients without DS), NYC [25] and Spain [24]). B., C. and D. Mortality rates among hospitalized individuals. Hospitalized individuals with Down syndrome from the UK ISAR-
IC4C and the T21RS surveys are compared to matched individuals without Down syndrome (controls) from the ISARIC4C survey. The 100 individuals with Down syndrome
reported through the UK ISARIC4C survey were matched to 400 individuals without Down syndrome (controls) from the same survey (matching 1:4) as well as to 100 individuals
with Down syndrome from the T21RS survey (matching 1:1). As samples were matched based on age, gender and ethnicity, mortality rates are corrected for these characteristics
(see supplementary tables S2 and S3 for more information on the matched samples). We had information on the outcome of disease in 91/100 individuals from the matched T21RS
dataset. B. All matched individuals. C.Matched individuals younger than 40 years of age. D.Matched individuals 40 years of age or older.
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8 A. H€uls et al. / EClinicalMedicine 00 (2021) 100769than for their siblings without DS [29]. Therefore, it may be difficult
to detect, discriminate, and report pain in patients with DS. Like pain,
nausea has to be self-reported by the patient. Hence, it is possible
that both pain and nausea were underreported in individuals with
DS and poorly detected and documented by clinicians. This possibility
highlights the importance of including family members/caregivers in
the clinical assessment of COVID-19 patients with DS to avoid under-
representation of self-reported symptoms.
Mortality rates could only be compared among hospitalized
COVID-19 patients with and without DS. We know that mortality
rates among all individuals with COVID-19 can be sensitive to report-
ing bias and to the amount of testing that is done in the population.
For the US, the CDC reported a hospitalization rate of 14% (16% of
these were admitted to an ICU) and a mortality rate of 5% [30]. In the
T21RS survey sample, the admission rate to the ICU was 50% among
all hospitalized individuals with DS; this proportion was almostPlease cite this article as: A. H€uls et al., Medical vulnerability of individua
21 Research Society and the UK ISARIC4C survey, EClinicalMedicine (2021identical between clinician (49.7%) and caregiver reports (49.5%) and
is much higher than the one reported in the general population in
the UK (17%) [23]. This can be another indicator of more severe out-
comes of disease in individuals with DS.
Hospitalized individuals with DS were around three times more
likely to die than individuals without DS, assuming the same age,
gender and ethnicity, and this association was only slightly attenu-
ated when adjusted for known risk factors for COVID-19-related mor-
tality. However, additional analysis showed that children and young
adults (younger than age 40) were about 90% less likely to die once
admitted to hospital with COVID-19 in comparison to older adults
with DS. Nevertheless, pulmonary medical complications (pneumo-
nia and Acute Respiratory Syndrome) were more prevalent and dead-
lier in individuals with DS, which is in line with the more severe
complications during other viral respiratory infections such as influ-
enza and RSV [5].ls with Down syndrome to severe COVID-19data from the Trisomy
), https://doi.org/10.1016/j.eclinm.2021.100769
Fig. 3. Risk factors associated with adverse outcomes of COVID-19 in individuals with Down syndrome from the T21RS survey. Associations with A. hospitalization and B. mortality
in symptomatic COVID-19 patients with Down syndrome from the T21RS survey estimated in adjusted logistic regression models (odds ratios (OR) and 95%-confidence intervals
(95%-CI)). Associations with age and gender were adjusted for the data source (caregiver versus clinician survey) and associations with living situation, level of IDD and comorbid-
ities were adjusted for age, gender, data source and country of residence. Abbreviations: IDD, intellectual and developmental disabilities; ref, reference category.
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in COVID-19 patients with DS, which is in line with findings from the
general population as reported in previous results from the ISARIC4C
survey [23]. Importantly, we observed an increased mortality rate
from age 40, at much earlier age than in the general population.
Many markers of accelerated aging have been well documented in
individuals with DS [31], chief among them being the premature
development of Alzheimer’s disease pathology and dementia. This
emphasizes the need to protect older individuals with DS from SARS-
CoV-2 infections. While mortality rates among children and young
adults with DS were low, they were still higher than in individuals
without DS from the same age groups; however more data are
needed to confirm this pattern.
Additional risk factors for hospitalization were male gender, obe-
sity, diabetes and congenital heart defect and those for mortality
were male gender and Alzheimer’s disease/dementia. As most of
these are known risk factors for severe outcomes of COVID-19 [23],
our findings suggest that the risk factors for individuals with DS are
similar to those observed in the general population. However as obe-
sity, dementia and congenital heart defect occur at higher rate in DS
than the general population, their role in increasing risk for severe
outcomes in this population is highly significant.
Except for congenital heart defects, we did not identify any other risk
factors that were specific for individuals with DS. More studies with
larger sample sizes may be needed to investigate whether other com-
mon comorbidities of DS (e.g. obstructive sleep apnea, gastroesophageal
reflux, or seizures) increase the risk for a severe course of COVID-19. Of
note, we did not find any indication that living in residential care facili-
ties or the level of intellectual disability increases the risk for COVID-19
related hospitalization or mortality. It has been reported that individuals
living in residential care facilities are more vulnerable to COVID-19
infection [32], but it has also been noted by other authors “that people
with [intellectual and developmental disabilities] living in congregate
care settings can benefit from a coordinated approach to infection con-
trol, case identification and cohorting” [33]. Possibly as evidence of ade-
quate management or rapid response in many of these facilities, we
observed in our study population that infected individuals in congregate
care settings were not more vulnerable to adverse outcomes of disease
than those living with their families.
Including both family and clinician reports has the advantage
of capturing information from a broad spectrum of severity ofPlease cite this article as: A. H€uls et al., Medical vulnerability of individua
21 Research Society and the UK ISARIC4C survey, EClinicalMedicine (2021COVID-19 and individuals from all age groups, which is in contrast to
most previous large-scale studies on COVID-19 that are based on hos-
pital reports(2325). In addition, our survey has been distributed in
many different countries, which increased the sample size and added
diversity to our study. Nonetheless, as a sample of convenience, our
study population might not be representative of the population of
individuals with DS at large.
The primary limitation of this study is that not all of the COVID-19
cases were confirmed by COVID-19-specific laboratory tests. Given
that our survey was launched at the beginning of the pandemic when
testing was scarce, we would have lost more than 20% of our cases
(particularly from Spain, France, and Italy) if we were to include only
individuals with laboratory-confirmed COVID-19. Nonetheless, the
comparison with individuals from the general population was
restricted to patients hospitalized with COVID-19, providing an added
level of confidence for the clinical diagnosis even when laboratory
tests were not reported. Another limitation of our study is the inclu-
sion of cases from different countries and thus different health sys-
tems. Some countries had more COVID-19 cases than others, health
care systems differ substantially between countries (e.g. India versus
Western European countries) and some countries experienced a surge
in cases later than others, so that they had more time to prepare and
develop treatment strategies. To address this potential bias, we con-
ducted the comparison to the general population for cases that were
matched based on age, gender and ethnicity; and adjusted the associa-
tion analyses with risk factors for hospitalization and mortality for
country of residence. Lastly, most COVID-19 patients from the T21RS
and in the ISARIC4C surveys were reported during the first wave of the
pandemic, when there were few treatment strategies available and
mechanical ventilation was often the only treatment for severe
COVID-19 cases with respiratory distress. It is unknown if anatomical
differences in the upper respiratory tract of individuals with DS are
linked to a poor survival rate after mechanical ventilation and if this
contributed to the high mortality rates during the first wave of the
pandemic.
The comparison with data from the general population also has
some limitations. The inclusion criteria are different between studies
due to limited testing capacity [2325]. Furthermore, we could only
compare data from hospitalized individuals and it is unknown
whether COVID-19 patients with DS are admitted more or less often
to hospitals and which factors or reasons may affect their rate ofls with Down syndrome to severe COVID-19data from the Trisomy
), https://doi.org/10.1016/j.eclinm.2021.100769
ARTICLE IN PRESS
JID: ECLINM [m5G;February 26, 2021;3:55]
10 A. H€uls et al. / EClinicalMedicine 00 (2021) 100769hospitalization. Lastly, the samples for the matched comparison were
from the UK, whereas the T21RS study samples came from many dif-
ferent countries and country-specific differences could have biased
our results. Furthermore, we cannot determine whether the 11
matched hospitalised T21RS cases from the UK were also part of the
ISARIC4C survey.
There are several open questions we could not answer with our
study. As our study only included individuals infected with SARS-
CoV-2, we could not address whether individuals with DS are more
likely to get infected. Furthermore, due to our limited sample size,
we were not able to identify any risk factors for a severe course of
COVID-19 that might be specific for individuals with DS. Another
question we could not specifically address is whether COVID-19
patients with DS are subject to significant discrimination that might
have affected the offer of invasive interventions. The high rates of ICU
admissions within our study sample, however, do not support this
hypothesis. Yet, it is possible that patients with DS may have been
admitted to ICU later than patients without DS due to delay in diag-
nosis.
Further research is required to establish whether treatments are
equally effective in individuals with DS, and whether specific treat-
ments are required to reduce the increased rate of severe outcomes
[1]. There should be a focus on preventing or ameliorating severe out-
comes, which includes prioritisation for immunisation (influenza,
pneumococcus, and SARS-CoV-2). In addition, our study sample only
includes a small number of asymptomatic cases (6%), likely due to
lack of routine testing; thus, it remains unknown whether trisomy 21
or DS-related comorbidities alter the risk of having symptoms after
infection with SARS-CoV-2.
Our results have implications for preventive and clinical manage-
ment of individuals with COVID-19 and DS. In terms of sheltering/
shielding individuals to prevent infection, special caution should be
taken with individuals over age 40, which is about 20 years younger
than the typical at-risk group in the general population. Individuals
with DS aged 40 and older have a three-fold increased risk for severe
outcomes compared to the general population, which is not explained
by additional comorbidities. Bearing in mind limited data, the present
study also suggests that younger individuals are unlikely to develop
severe disease, but more data are needed to confirm this supposition.
The T21RS survey shows that clinicians and caregivers should primar-
ily look for the same signs and symptoms seen in the general popula-
tion (e.g. fever, cough, shortness of breath) when monitoring for
COVID-19 in individuals with DS. Milder signs and symptoms such as a
‘runny nose’ can also be a sign of COVID-19, particularly in younger
patients with DS, which is often underreported. With this information
in mind, it is also safe to assume that most of the recommendations
given to the general population, such as limiting exposure by social
distancing and access to safe activities with respiratory protection, are
also important to prevent SARS-CoV-2 infection and spread of COVID-
19 among those with DS. Additional strategies include prioritising
individuals with DS for COVID-19 immunisations, as well as for flu and
pneumococcal vaccination, to reduce the risk for severe outcomes fol-
lowing infection with SARS-CoV-2.
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